Barbara J Turner1, Yuanyuan Liang. 1. Division of General Internal Medicine, Department of Medicine, University of Texas Health Science Center San Antonio (UTHSCSA), 7411 John Smith Rd. Suite 1050, San Antonio, TX, 78229, USA, turner@uthscsa.edu.
Abstract
BACKGROUND: Opioid analgesics and other psychoactive drugs may pose an even greater risk for drug overdose in persons with mental health disorders. OBJECTIVE: The purpose of this study was to examine interactions of filled prescriptions for opioids, benzodiazepines, antidepressants, and zolpidem with mental health disorders in regard to drug overdose. DESIGN: The study was a retrospective cohort review. SUBJECTS: Subjects were national HMO beneficiaries aged 18-64 years, enrolled at least 1 year (01/2009 to 07/2012), who filled at least two prescriptions for Schedule II or III opioids for non-cancer pain. MAIN MEASURES: The outcome was the first inpatient or outpatient drug overdose after the first filled opioid prescription. Predictors were calculated in 6-month intervals and exactly 6 months before a drug overdose: opioid use (mean daily morphine-equivalent dose), benzodiazepine use (days' supply), antidepressant use (days' supply), zolpidem use (days' supply), mental health disorders (depression, anxiety/PTSD, psychosis), pain-related conditions, and substance use disorders (alcohol, other drug). KEY RESULTS: A total of 1,385 (0.67%) subjects experienced a drug overdose (incidence rate 421/100,000 person-years). The adjusted odds ratios (AOR) for overdose among all subjects rose monotonically with daily opioid dose, but highest (AOR = 7.06) for persons with depression and a high opioid dose (≥100 mg) versus no depression or opioid use. Longer-term antidepressants (91-180 days) were protective for persons with depression, with 20% lower AORs for overdose versus short-term (1-30 days) or none. For persons without depression, the AORs of overdose were increased for antidepressant use, but greatest (AOR = 1.98) for short-term use versus none. The AORs of overdose increased with the duration of benzodiazepine therapy among all subjects, with over 2.5-fold higher AORs for 91-180 days versus none. CONCLUSIONS: Opioids and longer-duration benzodiazepines were associated with drug overdose among all subjects, but opioid risk was greatest for persons with depression. Antidepressant use > 90 days reduced the odds of overdose for persons with depression, but all antidepressant use increased the risk for persons without depression.
BACKGROUND: Opioid analgesics and other psychoactive drugs may pose an even greater risk for drug overdose in persons with mental health disorders. OBJECTIVE: The purpose of this study was to examine interactions of filled prescriptions for opioids, benzodiazepines, antidepressants, and zolpidem with mental health disorders in regard to drug overdose. DESIGN: The study was a retrospective cohort review. SUBJECTS: Subjects were national HMO beneficiaries aged 18-64 years, enrolled at least 1 year (01/2009 to 07/2012), who filled at least two prescriptions for Schedule II or III opioids for non-cancer pain. MAIN MEASURES: The outcome was the first inpatient or outpatientdrug overdose after the first filled opioid prescription. Predictors were calculated in 6-month intervals and exactly 6 months before a drug overdose: opioid use (mean daily morphine-equivalent dose), benzodiazepine use (days' supply), antidepressant use (days' supply), zolpidem use (days' supply), mental health disorders (depression, anxiety/PTSD, psychosis), pain-related conditions, and substance use disorders (alcohol, other drug). KEY RESULTS: A total of 1,385 (0.67%) subjects experienced a drug overdose (incidence rate 421/100,000 person-years). The adjusted odds ratios (AOR) for overdose among all subjects rose monotonically with daily opioid dose, but highest (AOR = 7.06) for persons with depression and a high opioid dose (≥100 mg) versus no depression or opioid use. Longer-term antidepressants (91-180 days) were protective for persons with depression, with 20% lower AORs for overdose versus short-term (1-30 days) or none. For persons without depression, the AORs of overdose were increased for antidepressant use, but greatest (AOR = 1.98) for short-term use versus none. The AORs of overdose increased with the duration of benzodiazepine therapy among all subjects, with over 2.5-fold higher AORs for 91-180 days versus none. CONCLUSIONS: Opioids and longer-duration benzodiazepines were associated with drug overdose among all subjects, but opioid risk was greatest for persons with depression. Antidepressant use > 90 days reduced the odds of overdose for persons with depression, but all antidepressant use increased the risk for persons without depression.
Authors: Amy S B Bohnert; Mark A Ilgen; Rosalinda V Ignacio; John F McCarthy; Marcia Valenstein; Frederic C Blow Journal: Am J Psychiatry Date: 2011-09-28 Impact factor: 18.112
Authors: Lynn R Webster; Susan Cochella; Nabarun Dasgupta; Keri L Fakata; Perry G Fine; Scott M Fishman; Todd Grey; Erin M Johnson; Lewis K Lee; Steven D Passik; John Peppin; Christina A Porucznik; Albert Ray; Sidney H Schnoll; Richard L Stieg; Wayne Wakeland Journal: Pain Med Date: 2011-06 Impact factor: 3.750
Authors: Amy S B Bohnert; Marcia Valenstein; Matthew J Bair; Dara Ganoczy; John F McCarthy; Mark A Ilgen; Frederic C Blow Journal: JAMA Date: 2011-04-06 Impact factor: 56.272
Authors: Jessica A Stewart; Deborah A Deliyannides; David J Hellerstein; Patrick J McGrath; Jonathan W Stewart Journal: J Clin Psychiatry Date: 2011-12-27 Impact factor: 4.384
Authors: Amy M Kobus; David H Smith; Benjamin J Morasco; Eric S Johnson; Xiuhai Yang; Amanda F Petrik; Richard A Deyo Journal: J Pain Date: 2012-11 Impact factor: 5.820
Authors: Jessica J Wyse; Benjamin J Morasco; Steven K Dobscha; Michael I Demidenko; Thomas H A Meath; Travis I Lovejoy Journal: J Opioid Manag Date: 2018 Jul/Aug
Authors: Cynthia I Campbell; Andrea H Kline-Simon; Michael Von Korff; Kathleen W Saunders; Constance Weisner Journal: Subst Use Misuse Date: 2017-03-27 Impact factor: 2.164
Authors: Theresa W Kim; Alexander Y Walley; Timothy C Heeren; Gregory J Patts; Alicia S Ventura; Gabriel B Lerner; Nicholas Mauricio; Richard Saitz Journal: J Subst Abuse Treat Date: 2017-07-14
Authors: G Thomas Ray; Amber L Bahorik; Paul C VanVeldhuisen; Constance M Weisner; Andrea L Rubinstein; Cynthia I Campbell Journal: Am J Manag Care Date: 2017-05-01 Impact factor: 2.229
Authors: Christopher Griggs; Stephen Wyatt; Meghan K Wally; Michael Runyon; Joseph R Hsu; Rachel B Seymour; Michael Beuhler; Michael J Bosse; Ryan Fogg; Michael Gibbs; Eric Haas; Steven Jarrett; Daniel Leas; Animita Saha; Sharon Schiro; Bradley Watling Journal: J Addict Med Date: 2019 Sep/Oct Impact factor: 3.702
Authors: Manu Thakral; Rod L Walker; Kathleen Saunders; Susan M Shortreed; Sascha Dublin; Michael Parchman; Ryan N Hansen; Evette Ludman; Karen J Sherman; Michael Von Korff Journal: Pain Med Date: 2018-12-01 Impact factor: 3.750